519 related articles for article (PubMed ID: 14551889)
1. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
Edghill-Smith Y; Venzon D; Karpova T; McNally J; Nacsa J; Tsai WP; Tryniszewska E; Moniuszko M; Manischewitz J; King LR; Snodgrass SJ; Parrish J; Markham P; Sowers M; Martin D; Lewis MG; Berzofsky JA; Belyakov IM; Moss B; Tartaglia J; Bray M; Hirsch V; Golding H; Franchini G
J Infect Dis; 2003 Oct; 188(8):1181-91. PubMed ID: 14551889
[TBL] [Abstract][Full Text] [Related]
2. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
Edghill-Smith Y; Bray M; Whitehouse CA; Miller D; Mucker E; Manischewitz J; King LR; Robert-Guroff M; Hryniewicz A; Venzon D; Meseda C; Weir J; Nalca A; Livingston V; Wells J; Lewis MG; Huggins J; Zwiers SH; Golding H; Franchini G
J Infect Dis; 2005 Feb; 191(3):372-81. PubMed ID: 15633096
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
4. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome.
Bartlett JG
Clin Infect Dis; 2003 Feb; 36(4):468-71. PubMed ID: 12567305
[TBL] [Abstract][Full Text] [Related]
5. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
6. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
[TBL] [Abstract][Full Text] [Related]
7. Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.
Kan VL; Manischewitz J; King LR; Golding H
AIDS; 2007 Feb; 21(4):521-4. PubMed ID: 17301573
[TBL] [Abstract][Full Text] [Related]
8. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
9. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
[TBL] [Abstract][Full Text] [Related]
10. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
Earl PL; Americo JL; Wyatt LS; Eller LA; Whitbeck JC; Cohen GH; Eisenberg RJ; Hartmann CJ; Jackson DL; Kulesh DA; Martinez MJ; Miller DM; Mucker EM; Shamblin JD; Zwiers SH; Huggins JW; Jahrling PB; Moss B
Nature; 2004 Mar; 428(6979):182-5. PubMed ID: 15014500
[TBL] [Abstract][Full Text] [Related]
12. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
Empig C; Kenner JR; Perret-Gentil M; Youree BE; Bell E; Chen A; Gurwith M; Higgins K; Lock M; Rice AD; Schriewer J; Sinangil F; White E; Buller RM; Dermody TS; Isaacs SN; Moyer RW
Vaccine; 2006 Apr; 24(17):3686-94. PubMed ID: 16430997
[TBL] [Abstract][Full Text] [Related]
13. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
[TBL] [Abstract][Full Text] [Related]
14. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
15. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
16. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
18. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
19. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
[TBL] [Abstract][Full Text] [Related]
20. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
